FDA Grants Interchangeable Status to Lupin's Ranibizumab Biosimilar

June 8, 2026 — Lupin Limited has secured a landmark FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Genentech's Lucentis (ranibizumab). The approval marks a significant milestone: Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States available in both vial and pre-filled syringe (PFS) formats, covering both the 0.3 mg and 0.5 mg strengths of the reference product.

The interchangeable designation is a critical regulatory advantage that allows pharmacists to substitute Ranluspec for Lucentis at the pharmacy level without requiring a new prescription or physician authorization. This automatic substitution capability dramatically reduces administrative barriers and is expected to accelerate biosimilar adoption among ophthalmologists and retina specialists.

Ranibizumab: A Complex Biologic Manufacturing Challenge

Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) that binds vascular endothelial growth factor A (VEGF-A), inhibiting neovascularization and vascular permeability in retinal diseases. The molecule presents several manufacturing complexities that create opportunities for specialized suppliers:

• Fragment antibody production: Unlike full-length monoclonal antibodies, Fab fragments require specialized expression systems and downstream processing to achieve high purity and correct folding
• High-concentration formulation: The ophthalmic indication demands ultra-pure, low-volume injectable formulations with stringent particulate and endotoxin specifications
• Dual presentation formats: Manufacturing both vials and pre-filled syringes requires distinct fill-finish capabilities and quality control processes
• Cold chain requirements: The biologic must maintain 2-8°C storage conditions throughout distribution, demanding specialized packaging and logistics

The $1 Billion Ophthalmic Biosimilar Opportunity

Lucentis generated approximately $630 million in global sales in 2024, with projections reaching $1.07 billion by 2031 at a CAGR of 8%. The ophthalmic biosimilar market is rapidly expanding as multiple reference biologics face patent challenges:

• Bevacizumab (Avastin): Off-label intravitreal use continues as a cost-effective alternative, though Lucentis maintains clinical preference for specific indications
• Aflibercept (Eylea): Biosimilar competition is intensifying, with Sandoz settling patent litigation to launch in late 2026
• Faricimab (Vabysmo): Next-generation bispecific antibody targeting VEGF-A and Ang-2, representing the emerging competitive landscape

API and Fill-Finish Supply Chain Implications

The expanding ranibizumab biosimilar market creates multiple opportunities across the pharmaceutical supply chain:

API Manufacturing:

• CHO cell line optimization for high-titer Fab fragment expression
• Protein A and ion exchange chromatography resins for capture and polishing steps
• Ultrafiltration/diafiltration systems for concentration and buffer exchange
• GMP-grade excipients including histidine, sucrose, and polysorbate 20

Fill-Finish Services:

• Pre-filled syringe manufacturing capacity for ophthalmic injectables
• Stoppers, plungers, and glass barrel components meeting USP standards
• Silicone oil-free syringe technologies for protein stability
• Sterile fill-finish in isolator or RABS configurations

Analytical and Quality Services:

• Potency assays including VEGF binding and cell-based bioassays
• Forced degradation and stability programs
• Particulate matter and subvisible particle characterization

Lupin's Growing Biologics Portfolio

This approval represents Lupin's second US biosimilar approval, reinforcing the company's strategic push into biologics. Headquartered in Mumbai, Lupin operates across more than 100 markets with 15 manufacturing sites and seven research centers globally. The company's biotechnology division, led by Dr. Cyrus Karkaria, has been building capabilities in biosimilar development, manufacturing, and commercialization.

CEO Vinita Gupta emphasized that the approval "expands patients' access to proven vision therapies," while Managing Director Nilesh Gupta highlighted the company's manufacturing capabilities and commitment to affordable treatments. The biologics portfolio positions Lupin as an emerging player in the global biosimilar market, competing with established players like Biocon, Samsung Bioepis, and Amgen.

Competitive Landscape in Ophthalmic Biosimilars

The ranibizumab biosimilar space is becoming increasingly competitive:

• Biogen (Byooviz): First ranibizumab biosimilar approved in the US, but without interchangeability designation
• Coherus BioSciences (Cimerli): Another ranibizumab biosimilar, also lacking interchangeability status
• Formycon/Coherus: Collaboration on further ophthalmic biosimilar development

Lupin's interchangeable status and dual presentation format (vial plus PFS) provide significant differentiation that could accelerate market penetration, particularly in pharmacy-level substitution scenarios.

Strategic Implications for B2B Suppliers

For pharmaceutical suppliers and contract manufacturers, the expanding ophthalmic biosimilar market presents several strategic opportunities:

• Specialized fill-finish partnerships: PFS manufacturing for ophthalmic biologics requires unique expertise in low-volume, high-precision filling
• Raw material supply: Culture media, purification reagents, and formulation excipients for biosimilar production
• Analytical reference standards: Reference materials for comparability testing and release assays
• Regulatory support: DMF filings and global regulatory dossier preparation for ophthalmic biologics
• Packaging components: Ophthalmic-specific delivery devices and packaging meeting light protection and temperature stability requirements

The ophthalmic biosimilar market is poised for significant growth as more reference biologics lose exclusivity and biosimilar manufacturers invest in interchangeable designations. Companies positioned early in the supply chain — from API production through fill-finish and packaging — stand to benefit from the accelerating adoption of affordable vision-saving therapies.